Skip to content

Isoniazid

PharmacologyRespiratoryNervousHepatic

Summary

Isoniazid (INH) is a first-line tuberculosis drug that inhibits mycolic acid synthesis. Major side effects include hepatotoxicity, peripheral neuropathy (prevented by B6), and drug-induced lupus.

Detail

INH is a prodrug activated by mycobacterial KatG to form INH-NAD adducts that inhibit mycolic acid synthesis. Major toxicities: hepatotoxicity (0.1-0.2%, worse >50 years and with alcohol), peripheral neuropathy (dose-related, especially in slow acetylators, prevented with pyridoxine B6 supplementation), drug-induced lupus, and seizures. Slow acetylators (NAT2 variants) accumulate INH, increasing toxicity risk. Monitor LFTs; hold if transaminases >3x ULN.

Sources

  • First Aid for the USMLE Step 1
  • Katzung Basic & Clinical Pharmacology
  • Harrison's Principles of Internal Medicine

Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.

Related pharmacology terms

Isoniazid — Medical Glossary